J Huober, B F Cole, M Rabaglio, A Giobbie-Hurder, J Wu, B Ejlertsen, H Bonnefoi, J F Forbes, P Neven, I Láng, I Smith, A Wardley, K N Price, A Goldhirsch, A S Coates, M Colleoni, R D Gelber, B Thürlimann
There may be a relationship between the incidence of vasomotor and arthralgia/myalgia symptoms and treatment outcomes for postmenopausal breast cancer patients with endocrine-responsive disease who received adjuvant letrozole or tamoxifen. Data on patients randomized into the monotherapy arms of the BIG 1-98 clinical trial who did not have either vasomotor or arthralgia/myalgia/carpal tunnel (AMC) symptoms reported at baseline, started protocol treatment and were alive and disease-free at the 3-month landmark (n = 4,798) and at the 12-month landmark (n = 4,682) were used for this report...
January 2014: Breast Cancer Research and Treatment